| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Immunology and Cell Biology, Research Center Borstel, Borstel, Germany;
Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany;
Department of Pathobiochemistry and Laboratory Medicine, University of Marburg, Marburg, Germany; and
Department of Pathology, Universitäts Klinikum Benjamin Franklin, Berlin, Germany
IL-15 has been shown to accelerate and boost allergic sensitization in mice. Using a murine model of allergic sensitization to OVA, we present evidence that blocking endogenous IL-15 during the sensitization phase using a soluble IL-15R
(sIL-15R) suppresses the induction of Ag-specific, Th2-differentiated T cells. This significantly reduces the production of OVA-specific IgE and IgG and prevents the induction of a pulmonary inflammation. Release of proinflammatory TNF-, IL-1
, IL-6, and IL-12 as well as that of Th2 cytokines IL-4, IL-5, and IL-13 into the bronchi are significantly reduced, resulting in suppressed recruitment of eosinophils and lymphocytes after allergen challenge. It is of clinical relevance that the airway hyper-responsiveness, a major symptom of human asthma bronchiale, is significantly reduced by sIL-15R treatment. Ex vivo analysis of the draining lymph nodes revealed reduced numbers of CD8, but not CD4, memory cells and the inability of T cells of sIL-15R-treated mice to proliferate and to produce Th2 cytokines after in vitro OVA restimulation. This phenomenon is not mediated by enhanced numbers of CD4+/CD25+ T cells. These results show that IL-15 is important for the induction of allergen-specific, Th2-differentiated T cells and induction of allergic inflammation in vivo.
This article has been cited by other articles:
|
|
 |
|
  H. P. Carroll, V. Paunovic, and M. Gadina Signalling, inflammation and arthritis: Crossed signals: the role of interleukin-15 and -18 in autoimmunity Rheumatology, September 1, 2008; 47(9): 1269 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Badoual, G. Bouchaud, N. E. H. Agueznay, E. Mortier, S. Hans, A. Gey, F. Fernani, S. Peyrard, P. L. -Puig, P. Bruneval, et al. The Soluble {alpha} Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer Cancer Res., May 15, 2008; 68(10): 3907 - 3914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sakuishi, S. Oki, M. Araki, S. A. Porcelli, S. Miyake, and T. Yamamura Invariant NKT Cells Biased for IL-5 Production Act as Crucial Regulators of Inflammation J. Immunol., September 15, 2007; 179(6): 3452 - 3462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bulanova, V. Budagian, E. Duitman, Z. Orinska, H. Krause, R. Ruckert, N. Reiling, and S. Bulfone-Paus Soluble Interleukin (IL)-15R{alpha} Is Generated by Alternative Splicing or Proteolytic Cleavage and Forms Functional Complexes with IL-15 J. Biol. Chem., May 4, 2007; 282(18): 13167 - 13179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Stoklasek, K. S. Schluns, and L. Lefrancois Combined IL-15/IL-15R{alpha} Immunotherapy Maximizes IL-15 Activity In Vivo J. Immunol., November 1, 2006; 177(9): 6072 - 6080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Rubinstein, M. Kovar, J. F. Purton, J.-H. Cho, O. Boyman, C. D. Surh, and J. Sprent Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha} PNAS, June 13, 2006; 103(24): 9166 - 9171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Lorenzen, A. J. Dingley, Y. Jacques, and J. Grotzinger The Structure of the Interleukin-15{alpha} Receptor and Its Implications for Ligand Binding J. Biol. Chem., March 10, 2006; 281(10): 6642 - 6647. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
